Pharming Q3 Revenue Up 21% to $117.6M; Guidance Tightened to $380-390M
PHAR sits 33% above its 52-week low of $9.11.
Summary
Pharming reported Q3 2026 revenue of $117.6M (+21% YoY), operating profit of $29.9M (+89%) and net profit of $22.4M, and tightened 2026 revenue guidance to $380-390M. RUCONEST returned to growth (+14%) and Joenja rose 58%.
Key Events · Earnings and Guidance · PHAR
-
Q3 Revenue Beats at $117.6M
Total revenues rose 21% to US$117.6M from US$97.3M in Q3 2025, above market expectations.
-
Operating Profit Nearly Doubles
Operating profit rose 89% to US$29.9M and net profit reached US$22.4M versus US$7.5M a year earlier; adjusted operating profit was US$35.0M excluding US$5.1M of inventory impairments.
-
RUCONEST Returns to Growth
RUCONEST revenue rose 14% to US$93.8M, reversing the 10% decline reported in Q2 2026, on stabilized U.S. demand and seasonal channel inventory build.
-
Guidance Tightened to $380-390M
Full-year 2026 revenue guidance narrowed to US$380M-US$390M from US$375M-US$395M, lifting the low end by US$5M.
Analysis · PHAR · Life Sciences
Pharming delivered the quarter it pre-announced on October 22 and filled in the rest: operating profit nearly doubled to $29.9M and net profit tripled to $22.4M, while cash rose to $190.9M. Full-year revenue guidance was narrowed to $380-390M from $375-395M, effectively lifting the floor by $5M. RUCONEST, the franchise that dragged in Q2 with a 10% decline, returned to 14% growth on stabilized U.S. demand, and Joenja grew 58% on German and Japanese launches. The next hard data point is CVID Phase II topline in November 2026, which determines whether leniolisib can be pushed into a far larger patient population than APDS.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $12.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $833.6M. The 52-week trading range was $9.11 to $21.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.